Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab. - Wikidata - wikimedia - TriplyDB

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

http://www.wikidata.org/entity/Q38692257

about

Hydradenitis suppurativa and inflammatory bowel disease: An unusual, but existing association Ustekinumab for the treatment of Crohn's disease.The Correlation of Serum IL-12B Expression With Disease Activity in Patients With Inflammatory Bowel Disease Efficacy and safety of ustekinumab in the induction therapy of TNF-α-refractory Crohn's disease patients: a systematic review and meta-analysis.Positioning ustekinumab in Crohn's disease: from clinical evidence to clinical practice.Top-down approach to biological therapy of Crohn's disease.Biological therapy targeting the IL-23/IL-17 axis in inflammatory bowel disease.Ustekinumab: a novel therapeutic option in Crohn's disease.Next generation of biologics for the treatment of Crohn's disease: an evidence-based review on ustekinumab.Ustekinumab use in Crohn's disease: a Canadian tertiary care centre experience.Clinical, endoscopic and radiographic outcomes with ustekinumab in medically-refractory Crohn's disease: real world experience from a multicentre cohort.Long-term efficacy and safety of ustekinumab in 122 refractory Crohn's disease patients: a multicentre experience.Clinical utility of ustekinumab in Crohn's disease.Long-term Maintenance of Clinical, Endoscopic, and Radiographic Response to Ustekinumab in Moderate-to-Severe Crohn's Disease: Real-world Experience from a Multicenter Cohort Study.Emerging Therapies for Inflammatory Bowel Disease

P2860

Q26745455-35F1291C-A99F-4EBA-ABF4-AD298B6B8ABC Q30390909-F5C16BCE-2408-429C-80EF-CF7C8FD20D51 Q37003637-A79FD727-6138-4071-8941-F0CDFE72948D Q38702997-A99D5B38-4F48-4F16-A99E-552A8CB535E0 Q38748380-0CA4AF12-ED7C-45AF-A249-32794C1DDE85 Q38764671-0C34CE27-A642-48ED-BB04-C02249D9E915 Q38798137-2EA5D843-C37F-43A8-BB39-99544D463B70 Q38875961-45DAC3A1-316B-4ECC-A4FB-BFE7879821B4 Q47141159-0C7C08B5-6889-4515-897B-AE401106AB04 Q48014899-6AD663E9-0FB1-40AB-8A7B-9A898BEF38BA Q48172992-5D04B0A8-982A-4744-A88A-640EB9886A6C Q48282663-6CFA0F08-A0D4-4BAD-9AD2-AD236FAC0390 Q49218809-99D7506A-9744-42F9-9043-3087CB14632C Q50782815-7ACB173B-F8AA-4B11-9D04-8909C9CF8DFA Q58099968-CD0E98D6-CB08-4A6F-89A3-74436EEE601E

P2860

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

http://www.wikidata.org/entity/Q38692257

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

@en

type

label

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

@en

prefLabel

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

@en

P1433

Q38692257-966B2074-7A65-46F3-ADF2-5934FAFCA2CB

P1476

Q38692257-FC6D1442-E34B-47AE-A678-CD65D52338D9

P2093

Q38692257-0246699D-D6C1-45C0-B831-F28E1AC1C44F

Q38692257-0A7A82F0-79F6-4D40-AAAD-4B542AD367D0

Q38692257-22560610-22B8-4E83-8036-586F9F9F37C1

Q38692257-2FC4FBD3-C5E2-4F7F-AC54-AE55348B788A

Q38692257-4007647E-1864-4F84-911B-7BA0AF9C0937

Q38692257-7E0FEBFB-8005-4325-A8A2-37F288C30100

Q38692257-971D43ED-DCBA-43EA-9E60-66606305DE6C

Q38692257-B7010DCF-1B89-410C-B21D-720CEB108CFB

Q38692257-C93988BC-35CF-45C2-A2B6-D239FE5E3447

P2860

Q38692257-11BF3A3C-5D60-45A8-A659-E2EC7E313998

Q38692257-2154D9C1-A417-4952-8792-D450567FB9F9

Q38692257-4370EE68-97F9-4D00-A1D8-BC03E6919C16

Q38692257-5727E3F2-A00B-4FA9-AFC1-5FC0C80C2938

Q38692257-5C865C5C-D506-42B4-BD4A-4B0D612C5511

Q38692257-694F3262-A03E-4663-B99E-9575F1BC421A

Q38692257-6AD6AC43-1537-4D5A-B1E4-5CB2A8139AFB

Q38692257-6D8865AA-F19C-403C-B729-83C5E1AF4973

Q38692257-6FFC0968-E156-430E-BED0-8C9BCA6EF48F

Q38692257-70749ACC-F305-43B8-B471-FA1ADB2E44AE

P304

Q38692257-C4576A6A-5452-4587-BE85-7EBB8B2A4ED3

P31

Q38692257-7AFA6317-1968-4D7D-80A4-0AB67A435527

P356

Q38692257-F0AB3700-8384-43E5-AC87-F3D2A27BEC8B

P433

Q38692257-801D0462-C220-4B61-8558-369C1F167775

P478

Q38692257-CFC66607-3E35-4225-8821-CFDD15A30912

P577

Q38692257-EF033C4E-19E7-4547-86D2-1C48275B2441

P698

Q38692257-0E25AE04-CBD5-449A-BE7A-AB7735B7B18E

P356

MIB.0000000000000624

P1433

Inflammatory Bowel Diseases

P1476

Patients with Refractory Crohn's Disease Successfully Treated with Ustekinumab.

@en

P2093

Akash Gadani

http://www.w3.org/2001/XMLSchema#string

Anne Nohl

http://www.w3.org/2001/XMLSchema#string

Caroline Duley

http://www.w3.org/2001/XMLSchema#string

David A Schwartz

http://www.w3.org/2001/XMLSchema#string

Dawn Beaulieu

http://www.w3.org/2001/XMLSchema#string

Kim Annis

http://www.w3.org/2001/XMLSchema#string

Kimberly A Harris

http://www.w3.org/2001/XMLSchema#string

Leyla Ghazi

http://www.w3.org/2001/XMLSchema#string

Sara Horst

http://www.w3.org/2001/XMLSchema#string

P2860

Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial

Interleukin-12 and Th1 immune response in Crohn's disease: pathogenetic relevance and therapeutic implication

Crohn's disease

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders.

Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial.

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis.

The incidence and prevalence of inflammatory bowel disease among U.S. veterans: a national cohort study.

Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.

P304

397-401

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MIB.0000000000000624

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

22

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-08T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26752468

http://www.w3.org/2001/XMLSchema#string